Press Releases
  Date Title View
Dec 18, 2013
-- Live Webcast Available at 9:15 am ET -- SAN DIEGO, Dec. 18, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, will ring the Opening Bell at the NASDAQ MarketSite in New York today in honor of Conatus' success...
Dec 2, 2013
SAN DIEGO, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Conatus' drug candidate emricasan for the ...
Nov 25, 2013
SAN DIEGO, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that its management team will present at the following upcoming conferences in December:Piper Jaffray 25th AnnualHealthcare Conference...
Nov 14, 2013
SAN DIEGO, Nov. 14, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the third quarter ended September 30, 2013. "In the third quarter, we continued to further advance the clini...
Nov 7, 2013
SAN DIEGO, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the third quarter ended September 30, 2013 on Thursday, November 14, 2013. Conatus's manageme...
Nov 2, 2013
Normal levels of apoptosis and caspase activity in healthy volunteers are not reduced by emricasanEmricasan currently in Phase 2b study in acute-on-chronic liver failure and Phase 2 study in severe alcoholic hepatitis SAN DIEGO, Nov. 2, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the develo...
Sep 25, 2013
SAN DIEGO, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that its management team will present a company overview at the 12th Annual BIO Investor Forum on Tuesday, October 8, 2013 at 4:30 p....
Sep 24, 2013
SAN DIEGO, Sept. 24, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will be included in the Russell 2000®, Russell 3000® and Russell Global Indices, effective Monday, September 30, 20...
Sep 11, 2013
SAN DIEGO, Sept. 11, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced initiation of active patient recruitment in a Phase 2b clinical trial of emricasan in patients with acute-on-chronic liver failure (A...
Sep 10, 2013
SAN DIEGO, Sept. 10, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced initiation of dosing in the Phase 2 clinical trial of emricasan in patients with severe alcoholic hepatitis. This study is being cond...
FirstPrevious
...
11
NextLast
= add release to Briefcase